Risk factor modification: rationale for management of dyslipidemia.

  title={Risk factor modification: rationale for management of dyslipidemia.},
  author={Antonio M. Gotto},
  journal={The American journal of medicine},
  volume={104 2A},
A number of recent clinical trials have clearly demonstrated the efficacy of cholesterol lowering as a risk-reduction strategy for the primary and secondary prevention of coronary artery disease (CAD). The Scandinavian Simvastatin Survival Study (4S), the West of Scotland Coronary Prevention Study (WOSCOPS), and the Cholesterol and Recurrent Events (CARE) trial, as well as numerous other investigations, have established that decreasing elevated levels of low-density lipoprotein (LDL… CONTINUE READING